Xilio Therapeutics, Inc. Deferred Offering Costs
Xilio Therapeutics, Inc. (XLO) had Deferred Offering Costs of $3.40 million as of 2021-09-30, per its 10-Q filed 2021-12-02.
Discontinued › Balance Sheet › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2021-12-02
- 2021-09-30: Deferred Offering Costs $3.40M.
- 2020-12-31: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2021-09-30 | $3.40M 10-Q · filed 2021-12-02 |
| 2020-12-31 | $0.00 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |